TB-500 vs Ipamorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
A synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.
Also: IPAM, NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Key Comparison Insights
- TB-500 is categorized as Healing, while Ipamorelin is Growth Hormone.
- Ipamorelin has stronger research evidence (Human Trials) compared to TB-500 (Animal Studies).
Detailed Comparison
| Attribute | TB-500 | Ipamorelin |
|---|---|---|
| Category | Healing | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | TB-500 is derived from the active region of the full Thymosin Beta-4 protein. It promotes cell migration by binding to and sequestering actin, a protein essential for cell movement. It upregulates actin expression, promotes angiogenesis, reduces inflammation, and facilitates hair follicle stem cell migration for wound healing. | Ipamorelin binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Unlike other GHRPs, it does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH. |
| Common Dosing | 2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) 2x weekly for 4-6 weeks, then 1x weekly | 200-300 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous or intramuscular injection | Subcutaneous injection |
| Typical Duration | 4-6 weeks loading, then maintenance | 8-12 weeks typical |
| Best Time to Take | Morning or evening | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Animal studies show significant wound healing acceleration, cardiac tissue repair, and anti-inflammatory effects. Note: Phase 2 human trials exist for full Thymosin Beta-4 protein (not TB-500 specifically) - 73-patient venous stasis ulcer trial showed ~25% achieved complete healing at 3 months. Ophthalmologic trials for dry eye also completed. However, TB-500 fragment itself has no human clinical trials. FDA restricted TB-500 from compounding under Category 2. WADA prohibited at all times. | Phase II trials for postoperative ileus showed good safety but failed to meet efficacy endpoints and were discontinued. Research demonstrates dose-dependent GH release with minimal side effects, improved bone density in postmenopausal women, and potential benefits for muscle mass and recovery. |
Frequently Asked Questions: TB-500 vs Ipamorelin
What is the difference between TB-500 and Ipamorelin?
TB-500 is a healing peptide that a synthetic 17-amino acid fragment of thymosin beta-4 (tb-4). unlike tb-4, tb-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. note: many vendors mislabel tb-4 as 'tb-500' in premixed products. Ipamorelin is a growth hormone peptide that a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. considered one of the safest ghrps. The main differences lie in their mechanisms of action and clinical applications.
Which is better, TB-500 or Ipamorelin?
Neither is universally "better" - the choice depends on your specific goals. TB-500 is typically used for healing purposes, while Ipamorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can TB-500 and Ipamorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using TB-500 and Ipamorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.